力尔凡配合外照射治疗晚期非小细胞肺癌的临床研究

Combination of Lifein and Radiotherapy in Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)

目的 :观察力尔凡与放疗合并应用对晚期非小细胞肺癌的疗效。方法 :40例晚期非小细胞肺癌患者随机分为综合组 (力尔凡 +放疗 )、单纯放疗组。综合组放疗开始即行力尔凡 10mg +0 .9%N .S 2 5 0ml静点 ,3次 /周 ,共 6周。两组放疗方法、剂量相同。结果 :综合组、单纯放疗组有效率分别是 75 %、45 % ,P <0 .0 5。综合组治疗后与治疗前比CD4 + 、CD4 + /CD8+ 比值升高 ,P >0 .0 5。CD56+ 升高 ,P <0 .0 5。CD8+ 下降 ,P >0 .0 5。而单纯放疗组治疗后与治疗前比CD4 + 、CD4 + /CD8+ 比值 ,CD56+ 显著下降 ,P <0 .0 5。CD8+ 升高 ,P <0 .0 5。两组治疗后上述各项指标相比差异显著 ,P <0 .0 1。结论 :力尔凡与放疗合并应用 ,治疗晚期非小细胞肺癌患者疗效优于单纯放疗 ,并能改善其细胞免疫功能。

Purpose: To observe the effect of Lifein combined with radiotherapy for advanced NSCLC. Methods: Forty cases of advanced NSCLC patients were randomized into general treatment (GT) group (Lifein+radiotherapy) and radiotherapy (RT) group. At the beginning of radiotherapy in GT group, Lifein 10mg. in 0.9% NS 250ml. was dropped three times weekly. These two groups received the same method and dosage of radiation. Results: Overall response rate of GT group and RT group were 75% and 45% respectively ( P <0.05). As the effect of the GT group was compare with before treatment, CD 4 +, CD 4 +/CD 8 +increased and CD 8 +decreased ( P >0.05) and CD 56 +increased ( P <0.05), while the same contrast in the RT group showed that CD 4 +, CD 4 +/CD 8 +, CD 56 +decreased significantly ( P <0.05) and CD 8 +increased ( P <0.05). Significant difference of the above indices existed between these two groups after treatment.( P <0.01). Conclusion: Lifein combined with radiotherapy might impove the treatment of NSCLC and increase the cell immunity function.